Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer

BACKGROUND: Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1 and 2 studies in this setting. The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerner, Gerald SMA, van Dullemen, Leon FA, Wiegman, Erwin M, Widder, Joachim, Blokzijl, Edwin, Driever, Ellen M, van Putten, John WG, Liesker, Jeroen JW, Renkema, Tineke EJ, Pieterman, Remge M, Mertens, Marc JF, Hiltermann, Thijo JN, Groen, Harry JM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262382/
https://www.ncbi.nlm.nih.gov/pubmed/25174943
http://dx.doi.org/10.1186/1748-717X-9-190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262382/
https://www.ncbi.nlm.nih.gov/pubmed/25174943
http://dx.doi.org/10.1186/1748-717X-9-190

Ejemplares similares